The APOBEC3A Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MCF-7 breast adenocarcinoma cell line, designed to ablate gene function through targeted gene disruption. This polyclonal format provides a heterogeneous pool of edited cells, avoiding clonal selection bias while maintaining a uniform loss-of-function background. The product is intended as a robust tool for investigating APOBEC3A-mediated processes in a breast cancer context, offering researchers a ready-to-use cellular model for downstream applications in cancer biology, innate immunity, and DNA damage research.
The parental MCF-7 cell line is a widely used human breast adenocarcinoma model, characterized by an epithelial morphology and a luminal A molecular subtype with estrogen receptor (ER) and progesterone receptor (PR) positivity, and HER2 negativity. This line has been instrumental in breast cancer research for decades, serving as a standardized platform for studying hormone-responsive tumor biology, drug responses, and oncogenic signaling. Its well-documented genetic landscape and growth characteristics make it an ideal host for generating a knockout model to dissect the specific contributions of APOBEC3A in mammary epithelial cells.
APOBEC3A encodes a single-stranded DNA cytidine deaminase that catalyzes C-to-U editing in DNA and RNA, functioning as a key factor in antiviral innate immunity and retrotransposon restriction. Its expression is strongly activated by type I interferons through an IFNAR-JAK1/TYK2-STAT1-IRF1 signaling axis, and also regulated by NF-??B. Once induced, APOBEC3A interacts with UNG and AGO2 to modulate DNA damage responses, leading to C-to-T mutations and activation of genomic instability pathways. The protein thus sits at the intersection of innate immune signaling and DNA damage repair, downstream of RIG-I/MDA5/MAVS/IRF3 sensing and upstream of ??H2AX-mediated damage signaling.
In the context of breast cancer, APOBEC3A has been implicated as a major source of APOBEC signature mutations, which are prevalent in many tumor genomes and contribute to tumor heterogeneity and acquired drug resistance. The MCF-7 host line expresses functional interferon signaling components, making it permissive for inducible APOBEC3A expression and thus an excellent model for studying interferon-driven mutagenesis. By disrupting the APOBEC3A gene in this line, researchers can dissect its role in generating mutation burdens, activating DNA damage checkpoints, and modulating sensitivity to genotoxic therapies, while also exploring its antiviral functions in an epithelial cell environment.
This knockout model is applicable to a diverse set of experimental investigations, including CRISPR screens for mutational signatures, drug sensitivity assays for APOBEC3A-induced genomic instability, and antiviral restriction factor research. Users can validate knockout status via western blot or RT-qPCR, measure cytidine deaminase activity, and assess DNA damage responses using immunofluorescence for ??H2AX or mutation detection assays like 3D-PCR. Flow cytometry and cell viability assays enable functional studies of apoptosis and proliferation. For additional details or technical support, please contact Ascent Research.
